Document is current
Any future updates will be listed below
-
Authors
Humer, Dominik https://orcid.org/0009-0008-2167-9346
Klepsch, Victoria https://orcid.org/0000-0003-4146-4664
Rieder, Dietmar https://orcid.org/0000-0003-1754-690X
Hölzl, Isabel
Schreiber, Daniel
Lang, Viktor
Koutník, Jiří https://orcid.org/0000-0003-0904-0968
Peer, Sebastian
Sajinovic, Tajana
Wille, Viana
Fürst, Anna
Savic, Dragana
Diem, Gabriel https://orcid.org/0000-0002-8737-005X
Posch, Wilfried https://orcid.org/0000-0001-8955-7654
Skvortsova, Ira-Ida
Krogsdam, Anne
Sopper, Sieghart https://orcid.org/0000-0003-2265-1974
Kobold, Sebastian https://orcid.org/0000-0002-5612-4673
Trajanoski, Zlatko https://orcid.org/0000-0002-0636-7351
Siegmund, Kerstin
Thuille, Nikolaus
Gruber, Thomas
Wolf, Dominik https://orcid.org/0000-0002-4761-075X
Baier, Gottfried https://orcid.org/0000-0002-2085-8325
- License Information
-
More Information
Article History
Received: 22 November 2024
Accepted: 10 February 2026
First Online: 27 February 2026
Competing interests
: SK has received honoraria from Cymab, Plectonic, TCR2 Inc., Miltenyi, Galapagos, Novartis, BMS and GSK. SK is an inventor of several patents in the field of immuno-oncology. SK received license fees from TCR2 Inc and Carina Biotech. SK received research support from TCR2 Inc., Tabby Therapeutics, Catalym GmBH, Plectonic GmBH and Arcus Bioscience for work unrelated to the manuscript. V.K., J.K., K.S., D.H. and G.B. are inventors on patents related to immunological targets in the field of immuno-oncology. D.R., I.H., D.S., V.L., S.P., T.S., Z.S., V.W., A.F., G.D., W.P., I-I. S., A.K., S.S., Z.T. and T.G. declare no competing interests.
